Comment
doi: 10.1371/journal.pmed.0040346.
Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing
Affiliations
- PMID: 18052605
- PMCID: PMC2100139
- DOI: 10.1371/journal.pmed.0040346
Item in Clipboard
Comment
Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing
PLoS Med.
2007 Dec.
Abstract
The author discusses a new study that found a common mutation in the connection domain of reverse transcriptase, a mutation that confers resistance to two antiretroviral drug classes.
Conflict of interest statement
Comment on
-
N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.PLoS Med. 2007 Dec;4(12):e335. doi: 10.1371/journal.pmed.0040335. PLoS Med. 2007. PMID: 18052601 Free PMC article.
Similar articles
-
N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.PLoS Med. 2007 Dec;4(12):e335. doi: 10.1371/journal.pmed.0040335. PLoS Med. 2007. PMID: 18052601 Free PMC article.
-
A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy.J Infect Dis. 2011 Sep 1;204(5):741-52. doi: 10.1093/infdis/jir385. J Infect Dis. 2011. PMID: 21844300
-
Antiretroviral Resistance Mutations (revised April 2001).HIV Clin Trials. 2001 Jul-Aug;2(4):346-55. doi: 10.1310/8FXB-B0EK-D525-BVU3. HIV Clin Trials. 2001. PMID: 11590539 No abstract available.
-
A fossil record of zidovudine resistance in transmitted isolates of HIV-1.Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13485-7. doi: 10.1073/pnas.251559398. Proc Natl Acad Sci U S A. 2001. PMID: 11717419 Free PMC article. Review. No abstract available.
-
[Resistance profile of rilpivirine].Enferm Infecc Microbiol Clin. 2013 Jun;31 Suppl 2:36-43. doi: 10.1016/S0213-005X(13)70141-1. Enferm Infecc Microbiol Clin. 2013. PMID: 24252532 Review. Spanish.
Cited by
-
Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens.Antimicrob Agents Chemother. 2011 Jun;55(6):2872-9. doi: 10.1128/AAC.01695-10. Epub 2011 Apr 4. Antimicrob Agents Chemother. 2011. PMID: 21464253 Free PMC article.
-
Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase.J Acquir Immune Defic Syndr. 2011 Apr;56(4):344-8. doi: 10.1097/QAI.0b013e31820cf029. J Acquir Immune Defic Syndr. 2011. PMID: 21350368 Free PMC article.
-
The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains.Retrovirology. 2011 May 11;8:31. doi: 10.1186/1742-4690-8-31. Retrovirology. 2011. PMID: 21569325 Free PMC article.
-
Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms.J Biol Chem. 2008 Aug 8;283(32):22222-32. doi: 10.1074/jbc.M803521200. Epub 2008 Jun 10. J Biol Chem. 2008. PMID: 18547911 Free PMC article.
-
Prediction of mutational tolerance in HIV-1 protease and reverse transcriptase using flexible backbone protein design.PLoS Comput Biol. 2012;8(8):e1002639. doi: 10.1371/journal.pcbi.1002639. Epub 2012 Aug 23. PLoS Comput Biol. 2012. PMID: 22927804 Free PMC article.
References
-
- Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2003;37:113–128. - PubMed
-
- Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA) AIDS. 2002;16:369–379. - PubMed
-
- Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS. 2000;14:F83–F93. - PubMed
-
- Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS. 2002;16:209–218. - PubMed
-
- Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 1999;353:2195–2199. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
